Cipla reported INR5.55B in Net Income for its fiscal quarter ending in March of 2026.





Net Income Change Date
Arca Biopharma USD -29.58M 694K Dec/2025
aTyr Pharma USD 24.56M 50.3M Dec/2025
Bio Path USD -976K 3.62M Sep/2025
Brainstorm Cell Therapeutics USD -2.11M 797K Sep/2025
Capricor Therapeutics USD -30.17M 5.6M Dec/2025
Cara Therapeutics USD -5.53M 621K Sep/2025
Cipla INR 5.55B 1.21B Mar/2026
Dr.Reddys Laboratories INR 2.21B 9.89B Mar/2026
Esperion Therapeutics USD 61.83M 93.16M Dec/2025
Immunic USD -19.3M 6.28M Dec/2025
Infinity Pharmaceuticals USD -9.96M 1.09M Jun/2023
Minerva Neurosciences USD 1.44M 21.07M Dec/2024
Nektar Therapeutics USD -36.08M 978K Dec/2025
Sangamo BioSciences USD -36.13M 12.96M Jun/2024
Sun Pharmaceuticals INR 33.69B 2.51B Dec/2025
TherapeuticsMD USD -1.09M 356K Jun/2024
UPL INR 10.61B 6.65B Mar/2026